# Hodgkin Variant Richter's Transformation in the Absence of Classical Risk Factors: A Rare Case With Spinal Manifestation

**Authors:** Evelin Kiss, Árpád Illés, Róbert Szász, Anna Rebeka Kovács, Gábor Méhes, Boglárka Brugós

PMC · DOI: 10.7759/cureus.103575 · Cureus · 2026-02-14

## TL;DR

A rare case of Hodgkin lymphoma transformation in a CLL patient without typical risk factors is reported, with successful treatment and good outcomes.

## Contribution

This case highlights a rare RT subtype with spinal involvement and absence of classical risk factors.

## Key findings

- The patient achieved complete metabolic remission after A+AVD therapy.
- The transformation occurred without typical CLL risk factors like TP53 mutation or IGHV status.
- HL-RT in this case had an unusual spinal manifestation.

## Abstract

Richter’s transformation (RT) is a feared and not completely understood complication of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). While most cases involve transformation to diffuse large B-cell lymphoma (DLBCL), CLL may, albeit rarely, progress to Hodgkin lymphoma (HL).

We report the case of a 74-year-old woman initially diagnosed with CLL/SLL who progressed to a rare form of HL subtype affecting the spinal cord. After receiving six cycles of brentuximab+doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy at our Department of Hematology (University of Debrecen), the patient achieved complete metabolic remission (CMR) and remains in good condition.

HL-RT in CLL is relatively rare and generally associated with poorer outcomes, though it is typically more favorable than DLBCL-RT. In this case report, we highlight not only an uncommon anatomical location of HL-RT but also the absence of typical predisposing factors, such as a TP53 mutation, unmutated immunoglobulin heavy chain (IGHV) status, or a lack of 13q deletion.

## Linked entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157], IGH (immunoglobulin heavy locus) [NCBI Gene 3492]
- **Chemicals:** doxorubicin (PubChem CID 31703), vinblastine (PubChem CID 13342), dacarbazine (PubChem CID 135398738)
- **Diseases:** chronic lymphocytic leukemia (MONDO:0004948), Richter’s transformation (MONDO:0002083), Hodgkin lymphoma (MONDO:0004952), diffuse large B-cell lymphoma (MONDO:0018905)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, IGHV3OR16-7 (immunoglobulin heavy variable 3/OR16-7 (pseudogene)) [NCBI Gene 28309] {aka IGHV3/OR16-7, IGHV3OR167}
- **Diseases:** RT (MESH:C537025), DLBCL (MESH:D016403), HL (MESH:D006689), CLL (MESH:D015451)
- **Chemicals:** A (MESH:D001151), brentuximab (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12991906/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12991906/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12991906/full.md

---
Source: https://tomesphere.com/paper/PMC12991906